BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Aggarwal M, Rozenbaum D, Bansal A, Garg R, Bansal P, McCullough A. Development of machine learning model to detect fibrotic non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00386-8. [PMID: 34400107 DOI: 10.1016/j.dld.2021.07.016] [Reference Citation Analysis]
2 Rowe IA, Parker R. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00598-X. [PMID: 34091047 DOI: 10.1016/j.cgh.2021.05.059] [Reference Citation Analysis]
3 Woolbright BL, Harris RA. PDK2: An Underappreciated Regulator of Liver Metabolism. Livers 2021;1:82-97. [DOI: 10.3390/livers1020008] [Reference Citation Analysis]
4 Park JG, Jung J, Loomba R. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors' reply. Aliment Pharmacol Ther 2021;54:216. [PMID: 34170539 DOI: 10.1111/apt.16462] [Reference Citation Analysis]
5 Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin Ther 2021:S0149-2918(21)00256-3. [PMID: 34400007 DOI: 10.1016/j.clinthera.2021.07.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]